NCT07155174 2026-03-17
SEZanne
AbbVie
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT04894591 2026-02-27
SCLC
Jazz Pharmaceuticals
Completed
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT04291937 2020-06-19
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
Jazz Pharmaceuticals
Approved for marketing
NCT01831089 2020-04-10
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
PharmaMar
Phase 1 Completed